Plain-English translation of NCT06228326 on ClinicalTrials.gov ↗ · Source last updated ·
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing a new experimental treatment called , which is an inhaled therapy designed to wake up your immune system to fight cancer in your lungs. is a special type of virus that has been engineered to be safe and to stimulate your body to produce immune-fighting substances directly in the tumor area. The trial will test whether this medication works alone or when combined with other approved cancer treatments like immunotherapy or .
Many patients with advanced lung cancer stop responding to standard treatments, and doctors need new options to help. This treatment aims to harness the body's own immune system to attack cancer cells in a different way than traditional therapies.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will receive the medication through inhalation (breathing it in like a nebulizer treatment) on a regular schedule—typically weekly for three weeks, then every three weeks, depending on which part of the study you're in. Some participants will receive this medication alone, while others will receive it combined with standard immunotherapy or drugs. You'll have regular clinic visits to monitor for side effects, have blood tests, and have imaging scans to see how your tumors are responding. Treatment continues until your cancer progresses, you experience unacceptable side effects, or you and your doctor decide to stop.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
United States